CAMP4 Therapeutics secures EU clearance to start Phase 1/2 ASCEND trial of CMP-002 for SYNGAP1 disorder
CAMP4 Therapeutics announced that regulators and ethics boards in several European Union member states have granted permission to launch its global Phase 1/2 ASCEND study of the antisense oligonucleotide CMP-002. The trial targets patients with SYNGAP1‑related disorder, a rare genetic condition with no disease‑modifying therapies. The company expects to dose the first participant in the fourth quarter of 2026. CEO Josh Mandel‑Brehm highlighted that the EU approval expands the trial’s geographic footprint following earlier clearances in the United Kingdom, Australia and Argentina.
Why it matters
The EU clearance enables CAMP4 to enroll European patients, potentially accelerating enrollment and data collection for its first‑in‑human study. Earlier dosing could allow the company to reach pivotal trial milestones sooner, which may affect its cash‑flow needs and valuation.
Key facts
- 1Regulatory authorities and ethics committees in multiple EU countries granted approval for the ASCEND Phase 1/2 trial of CMP-002. finance.yahoo.com
- 2CAMP4 plans to start dosing the first patient in the fourth quarter of 2026. investing.com
- 3CMP-002 is an investigational antisense oligonucleotide designed to increase SYNGAP1 gene expression. investing.com
- 4The company previously received trial clearances in the United Kingdom, Australia and Argentina. finance.yahoo.com
- 5SYNGAP1‑related disorder affects over 10,000 individuals in the United States and currently has no approved disease‑modifying treatments. finance.yahoo.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.